$0.6271
-0.017-2.64%
Last update: Nov 11, 4:43 PM
Virax Biolabs Group Ltd
VRAXNASDAQ
Virax Biolabs fell 94.6% from $11.58 to $0.63, behind the S&P 500's +9.8%. Its worst day was Jul 10 (−35.8%), and its low came Nov 11 at $0.63.
Nov 11, 2025 – Nov 11, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Virax Biolabs closed at its highest level of the year, 48.6% above where the year started.
+77.3% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that Virax Biolabs (UK) Limited, its wholly owned subsidiary, has achieved ISO 13485:2016 and ISO 9001:2015 certificat…
+33.9% · S&P 500 +2.9%
Virax Biolabs shares rose 59.8%, while the S&P 500 rose 1.0%.
+59.8% · S&P 500 +1.0%
Virax Biolabs shares rose 53.1%, while the S&P 500 fell 0.1%.
+53.1% · S&P 500 −0.1%
Virax Biolabs Group Limited (NASDAQ:VRAX) ("Virax" or the "Company") today announced that its wholly owned subsidiary, Virax Biolabs (UK) Limited, has entered into an exclusive multi-country commercial
+100.0%, the year's best day, on 72M shares, the year's heaviest volume · S&P 500 +0.8%
Virax Biolabs shares fell 32.9%, while the S&P 500 rose 0.3%.
−32.9% · S&P 500 +0.3%
Where it ended: a close of $0.63 on Nov 11, 2026.
Nothing in the past 12 months.
All VRAX earningsNothing in the past 12 months.
All VRAX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for VRAX and SPY from Benzinga historical bars. Not investment advice.
